Candidemia outcomes not improved with statin use
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Candidemia is an important cause of morbidity and mortality. As statins interfere with yeast membrane synthesis, we assessed whether use of statins during candidemia may cause differences in clinical outcomes. A retrospective review of 124 candidemia episodes during 2003-2008 in which all-cause and attributable mortality, length of stay and level of care were compared for patients who received and those who did not receive statins. A total of 124 candidemia events were observed involving 14 patients on statins and 110 without statins. Overall mortality in candidemia cases was 46%, but only 2% was attributed to candidemia. No differences were observed in clinical outcomes for the two groups of patients. During the last 2-year period of our study, there were higher rates of candidemia caused by non-C. albicans Candida spp., particularly those due to C. glabrata and C. parapsilosis. In conclusion, statin use during candidemia did not alter mortality, length of stay, or intensive care requirement of our patients, despite higher rates of non-C. albicans Candida species isolated during the last 2 years of our study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Dimopoulos, G., Ntziora, F., Rachiotis, G., Armaganidis, A., & Falagas, M. E. (2008) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181607262 · Cited by 189
Growth inhibition of Candida species and Aspergillus fumigatus by statins
Macreadie, I. G., Johnson, G., Schlosser, T., & Macreadie, P. I. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2006.00370.x · Cited by 136
Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata
Westermeyer, C., & Macreadie, I. G. (2007) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2006.00194.x · Cited by 73
Statins in candidemia: clinical outcomes from a matched cohort study.
Forrest, G. N., Kopack, A. M., & Perencevich, E. N. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-152 · Cited by 33
Biological consequences of statins in Candida species and possible implications for human health
Wikhe, K., Westermeyer, C., & Macreadie, I. G. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351529 · Cited by 31
Spanakis, E. K., Kourkoumpetis, T. K., Livanis, G., Peleg, A. Y., & Mylonakis, E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0447 · Cited by 31
Cited by
Tavakkoli, A., Johnston, T. P., & Sahebkar, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107483 · Cited by 73
Insights on the anticandidal activity of non-antifungal drugs
Moraes, D. C., & Ferreira-Pereira, A. (2019) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2019.07.004 · Cited by 37
Effect of Statin Use on Outcomes of Adults with Candidemia
Cuervo, G., Garcia-Vidal, C., Nucci, M., Puchades, F., Fernández-Ruiz, M., Mykietiuk, A., Manzur, A., Gudiol, C., Pemán, J., Viasus, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077317 · Cited by 20
“Another recent single-center study [28] did not show any benefit in the outcomes of patient with candidemia receiving statins.”
Is there a role for statins in fungal infections?
Bergman, P. W., & Björkhem-Bergman, L. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.856755 · Cited by 12
Effect of statin therapy on oral Candida carriage in hyperlipidemia patients: A pioneer study
Darwazeh, A., Al-Shorman, H., & Mrayan, B. (2022) · Dental and Medical Problems · doi:10.17219/dmp/142641 · Cited by 3
Metadata
- Authors
- Welch, M. L., Liappis, A. P., & Kan, V. L.
- Venue
- Medical Mycology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02
- Volume
- 51
- Issue
- 2
- Pages
- 219-222
- ISSN
- 0268-1218 (ISSN-L)
- 1369-3786
- 1460-2709
- OpenAlex
- W1969138760
- Cited by
- 16
- References
- 7
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.